2020 current operating income showed strong growth (+37.6% at constant rates and scope), reflecting the excellent evolution of revenue (+5.7% at constant rates and scope) and a sharp decrease in expenses in the context of the Covid-19 crisis

2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) 

Revenue grew +6.8% at constant exchange rates and scope at the end of September 2020 (+5.6% at constant rates) thanks to solid third quarter performance

Virbac will change its governance at its shareholders' meeting on December 15

Operating profit from ordinary activities up sharply for the first half of 2020 reflecting revenue resiliency and strong expenditure restraint during the Covid-19 crisis

Revenue grew by +5.0% at constant exchange rates in the first half of 2020 (+4.5% excluding Sentinel), impacted by a decline in the second quarter of the year

Virbac completes divestment of U.S. Rights to SENTINEL^® brands to MSD Animal Health

Virbac to divest U.S. Rights to SENTINEL^® brands to MSD Animal Health

2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying

2019 operating profit from ordinary activities on the rise

2019 annual revenue shows strong growth of +6.6% at constant exchange rates

Solid +8.4% growth in revenue at constant exchange rates at the end of September, 2019

Following the quarterly review of its indices, the Paris stock exchange operator, Euronext, includes Virbac in the CAC Mid 60 and SBF 120 as from 23 September.

Operating profit on the rise in the first half of 2019

Virbac announces the arrival of Cyrille Petit as a member of the supervisory board as of June 18, 2019. In addition, on the audit committee he will replace Olivier Bohuon, who is also a member of the supervisory board.

2019 first half-year revenue grew by +6.6% at constant exchange rates

2019 first quarter revenue rose by +10.9% at comparable exchange rates

2018 operating profit from ordinary activities grew by 13.4%

2018 annual revenue grew by +4.5% at constant exchange rates

Revenue grew by +5.5% at constant exchange rates at the end of September 2018

Operating profit up sharply in the first half of 2018

Revenue grew by +4.3% at constant exchange rates in the second quarter of 2018

2018 first quarter revenue rose by +3.3% at comparable exchange rates

Operating profit from ordinary activities 2017 comparable to 2016

Annual sales comparable to 2016 at constant exchange rates after strong fourth-quarter growth

By mutual agreement, Virbac and the other shareholders of Centrovet have decided to postpone the option to buy the Chilean aquaculture specialist for three years, under the same pricing conditions.

Virbac: quarterly sales affected by distributor destocking in the United States

On September 5, 2017, Virbac’s supervisory board co-opted Solène Madelpuech into the supervisory board as a new member. On the same day, Jeanine Dick, aged 81, announced her resignation. 

Slight increase in first half results

Virbac: second quarter sales growth largely offsets the decline in the first quarter

First quarter 2017 sales down, strongly impacted by stock effects in the distribution in the United States

Strong rebound in profitability in 2016  

Annual sales growth of 4.5%, at constant exchange rates

Virbac announces that it has received from the Food and drug administration (FDA) a communication confirming the lifting of the Warning Letter received in December 2015 for its St. Louis production site (Missouri, USA).

Sales grow by 3.2% at the end of September at constant rates

Growth of half-year results

Sales growth by 3.6% at constant exchange rates in the first half

Sales in the first quarter 2016 : return to organic growth

2015 annual results heavily impacted by the United States

Annual sales growth of 10.2%, driven by exchange rates and acquisitions

Virbac : sales grow by 5.5% in the third quarter

Half-year results  heavily impacted by the United States

Virbac : sales grow by 18.1% in the first half

Group’s perspectives for 2015 impacted by the industrial situation in the United-States

Sales growth of 17.1% in the first quarter

Virbac, listed on Euronext Paris

Results grow in 2014 following a strong second half

Sustained growth in the fourth quarter

Virbac announces the successful closing on January 2nd of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL^® Flavor Tabs^® and SENTINEL^® SPECTRUM^®, marketed up to now by Novartis Animal Health.

Virbac announces that it has entered into an agreement with Eli Lilly and Company to acquire major United States veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.

Confirmation of the rebound of growth in the third quarter

Half-year results impacted by foreign exchange and the low level of activity in the United States

Organic growth of 3% in the first half

Current operating profit increases by 6.9% in 2013

Rebound of growth in the last quarter

Slight rebound of organic growth in the third quarter

Slight increase of the current operating profit in the first half of 2013

Sales growth of 9.4% in the second quarter

Sales growth of 3.6% in the first quarter

A 15.8% net profit increase in 2012

Sales growth of 11.5% in 2012